pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Jul 8·1 min read
save

AI chatbots could provide companionship for people with dementia, but their role raises complex questions

Jul 8, 2026·read at STAT ↗Neutral

Jason Karlawish, a professor at the University of Pennsylvania, writes an opinion piece exploring how artificial-intelligence chatbots might be used in dementia care.

He recounts the story of Doug, a retired minister, whose boredom was alleviated when he spent hours talking with “Jane,” an AI chatbot that offered companionship and conversation, much to the relief of his wife Gabriella.

Karlawish notes that while such technology can provide meaningful interaction, it also raises difficult questions about the nature of care, ethical responsibilities, and how to integrate AI tools safely into the lives of people with cognitive impairment.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “Opinion: STAT+: What’s the right role for AI in dementia care?”

read at STAT ↗
417 words · retrieved Jul 8
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
University of Pennsylvania2
topics
Alzheimer's Disease6NeurologyPeptide Therapeutic

related stories

  • 20h agoGSK laying off 1.2K+ in BelgiumBioSpace
  • Sep 16Opinion: STAT+: Dementia should be a campaign issue — not an insultSTAT
  • Jul 28Opinion: STAT+: Dementia finally has a business modelSTAT
  • May 6Opinion: STAT+: Ambiguous loss: a peculiar kind of grief in dementia careSTAT
  • Sep 14Axoltis misses the mark in phase 2 ALS study, but will persevere with the synthetic peptideFierce Biotech